Guillain-Barre Syndrome in newly diagnosed multiple myeloma patients treated with bortezomib: Two case reports

Bortezomib is one of the mainstay treatments for patients with multiple myeloma (MM) in front line, relapsed, refractory and maintenance phases. Peripheral neuropathy is one of the most common adverse effect associated with its use. Herein we report two cases of Guillain-Barre syndrome in newly diagnosed MM patients treated with Bortezomib. The patients were treated with high-dose intravenous immunoglobulins and plasmapheresis with improvement in their symptoms. Guillain- Barre syndrome is a rare but serious adverse effect in newly diagnosed MM patients treated with Bortezomib. Immediate discontinuation of therapy and appropriate neurological work up should be initiated to confirm the diagnosis. It is prudent to recognize the association and avoid further Bortezomib therapy in these patients.